Evome Medical Technologies Inc.
LNDZF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $10,011 | $10,539 | $12,071 | $15,722 |
| % Growth | -5% | -12.7% | -23.2% | – |
| Cost of Goods Sold | $6,449 | $7,222 | $8,145 | $10,185 |
| Gross Profit | $3,562 | $3,317 | $3,926 | $5,537 |
| % Margin | 35.6% | 31.5% | 32.5% | 35.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $5,429 | $5,609 |
| SG&A Expenses | $3,210 | $3,699 | $5,429 | $5,609 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $808 | $817 | -$1,503 | -$72 |
| Operating Expenses | $4,018 | $4,516 | $3,926 | $5,537 |
| Operating Income | -$456 | -$1,199 | $0 | $0 |
| % Margin | -4.6% | -11.4% | 0% | 0% |
| Other Income/Exp. Net | -$693 | -$1,073 | -$4,286 | -$15,804 |
| Pre-Tax Income | -$1,149 | -$2,272 | -$4,286 | -$15,804 |
| Tax Expense | $0 | $12 | $0 | $9 |
| Net Income | -$1,149 | -$2,284 | -$4,286 | -$15,813 |
| % Margin | -11.5% | -21.7% | -35.5% | -100.6% |
| EPS | 0 | 0 | 0 | -0.209 |
| % Growth | – | – | 100% | – |
| EPS Diluted | 0 | 0 | 0 | -0.209 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 56,992 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 56,992 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $499 | $549 | $667 | $1,266 |
| Depreciation & Amortization | $1,807 | $348 | $485 | -$772 |
| EBITDA | $1,157 | -$1,375 | -$2,604 | -$13,286 |
| % Margin | 11.6% | -13% | -21.6% | -84.5% |